SecurityHLI / Houlihan Lokey, Inc. (441593100)
IndustryInvestment Advice
Common Shares Outstanding239,277,968 shares (as of 2017-12-31)
Total Insiders12
Total Directors7
Total Officers6

Stock Insider Trading (from SEC Form 4)

Houlihan Lokey, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

HLI / Houlihan Lokey, Inc. insiders include BEISER SCOTT L, Van de Bunt Bennet, GOLD IRWIN, HOTZ ROBERT H, SCHRIESHEIM ROBERT A, CRAIN CHRISTOPHER M, ORIX CORP Adelson Scott Joseph, KOSECOFF JACQUELINE B, PREISER DAVID A, ALLEY J LINDSEY, ORIX HLHZ Holding LLC, and .

Insider Roster

Insider Dir Off 10% Shares Owned
CRAIN CHRISTOPHER M GENERAL COUNSEL
X
ALLEY J LINDSEY Chief Financial Officer
X
PREISER DAVID A CO-PRESIDENT, Director
X X
BEISER SCOTT L CHIEF EXECUTIVE OFFICER, Director, 10% Owner
X X X
GOLD IRWIN EXECUTIVE CHAIRMAN, Director, 10% Owner
X X X
Adelson Scott Joseph CO-PRESIDENT, Director
X X
ORIX HLHZ Holding LLC 10% Owner
ORIX CORP 10% Owner
X 782,000
ORIX CORP 10% Owner
ORIX HLHZ Holding LLC 10% Owner
X
Van de Bunt Bennet Director
X 24,104
SCHRIESHEIM ROBERT A Director
X 18,224
KOSECOFF JACQUELINE B Director
X 6,042
HOTZ ROBERT H 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-18 4 ORIX HLHZ Holding LLC S D 3990621 -82,028 782,000 3,120,665,622,000
2018-05-17 4 ORIX HLHZ Holding LLC S D 5415514 -110,665 864,028 4,679,155,730,392
2018-05-16 4 ORIX HLHZ Holding LLC S D 1243518 -25,307 974,693 1,212,048,289,974
2018-05-09 4 ORIX HLHZ Holding LLC C D 561,760 1,000,000
2018-03-15 4 Adelson Scott Joseph S D 46.75 -13,732 0
2018-03-15 4 Adelson Scott Joseph C D 13,732 13,732
2018-03-15 4 ALLEY J LINDSEY S D 46.75 -22,549 0
2018-03-15 4 ALLEY J LINDSEY C D 22,549 22,549
2018-03-15 4 GOLD IRWIN S D 46.75 -20,728 0
2018-03-15 4 GOLD IRWIN C D 20,728 20,728
2018-03-15 4 CRAIN CHRISTOPHER M S D 46.75 -4,599 0
2018-03-15 4 CRAIN CHRISTOPHER M C D 4,599 4,599
2018-03-15 4 BEISER SCOTT L S D 46.75 -14,434 0
2018-03-15 4 BEISER SCOTT L C D 14,434 14,434
2018-03-15 4 PREISER DAVID A S D 46.75 -8,888 0
2018-03-15 4 PREISER DAVID A C D 8,888 8,888
2017-12-22 4 GOLD IRWIN G D -7,500 0
2017-12-22 4 GOLD IRWIN C D 7,500 7,500
2017-11-14 4 Adelson Scott Joseph G D -7,500 0
2017-11-14 4 Adelson Scott Joseph C D 7,500 7,500
2017-11-03 4 ORIX HLHZ Holding LLC S D 41.625 -125,000 438,240 18,241,740
2017-11-03 4 ALLEY J LINDSEY S D 41.625 -973 0
2017-11-03 4 ALLEY J LINDSEY C D 973 973
2017-11-03 4 GOLD IRWIN S D 41.625 -6,533 0
2017-11-03 4 GOLD IRWIN C D 6,533 6,533
2017-11-03 4 BEISER SCOTT L S D 41.625 -4,550 0
2017-11-03 4 BEISER SCOTT L C D 4,550 4,550
2017-11-03 4 CRAIN CHRISTOPHER M S D 41.625 -289 0
2017-11-03 4 CRAIN CHRISTOPHER M C D 289 289
2017-11-03 4 PREISER DAVID A S D 41.625 -2,801 0
2017-11-03 4 PREISER DAVID A C D 2,801 2,801
2017-11-03 4 Adelson Scott Joseph S D 41.625 -4,329 0
2017-11-03 4 Adelson Scott Joseph C D 4,329 4,329
2017-10-30 4 ORIX HLHZ Holding LLC S D 41.625 -1,750,000 563,240 23,444,865
2017-10-30 4 Adelson Scott Joseph S D 41.625 -60,589 0
2017-10-30 4 Adelson Scott Joseph F D 41.28 -30,094 60,589
2017-10-30 4 Adelson Scott Joseph C D 90,683 90,683
2017-10-30 4 ALLEY J LINDSEY S D 41.625 -13,538 0
2017-10-30 4 ALLEY J LINDSEY F D 41.28 -3,831 13,538
2017-10-30 4 ALLEY J LINDSEY C D 17,369 17,369
2017-10-30 4 BEISER SCOTT L S D 41.625 -63,688 0
2017-10-30 4 BEISER SCOTT L F D 41.28 -14,420 63,688
2017-10-30 4 BEISER SCOTT L C D 78,108 78,108
2017-10-30 4 CRAIN CHRISTOPHER M S D 41.625 -4,014 0
2017-10-30 4 CRAIN CHRISTOPHER M F D 41.28 -2,049 4,014
2017-10-30 4 CRAIN CHRISTOPHER M C D 6,063 6,063
2017-10-30 4 PREISER DAVID A S D 41.625 -39,215 0
2017-10-30 4 PREISER DAVID A F D 41.28 -10,263 39,215
2017-10-30 4 PREISER DAVID A C D 49,478 49,478
2017-10-30 4 GOLD IRWIN S D 41.625 -91,453 0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Identiv's (INVE) CEO Steven Humphreys on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good afternoon, and welcome to Identiv's Q1 2018 Earnings Call. My name is Devin and I will be your operator this afternoon. Joining us for today's presentation are the company's CEO, Steve Humphreys; and CFO, Sandra Wallach. Following management's remarks, we will open the call for questions. (4-0)

Orix Corporation's (IX) CEO Makoto Inoue on Q4 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Thank you very much for taking time out of your busy schedules to attend ORIX financial results briefing. Let me begin my presentation on consolidated results for fiscal year March 2018. Please refer to Page 2 of the handout. I'd like to start with the trends in net income and ROE. For fiscal year March 2018, net income was ¥313.1 billion, up 15% year-on-year. This represents a record high net income for 4 years in a row, and year-on-year net income growth for 9 years in a row. (4-0)

Houlihan Lokey's (HLI) CEO Scott Beiser on Q4 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good day, Ladies and gentlemen. Thank you for standing by. Please note that this call is being recorded today, May 9, 2018. I would now toll over to Christopher Crain, Houlihan Lokey's General Counsel. Please go ahead. (4-0)

Sainsbury's Asda buy could make UK tougher grocery market for Amazon

2018-05-01 reuters
LONDON (Reuters) - Sainsbury’s (SBRY.L) $10 billion purchase of Walmart’s (WMT.N) Asda may pressure UK grocery prices and make the British market less attractive for newer players such as Amazon.com (AMZN.O). (5-0)

Goldman, hedge funds drawn into Noble’s legal battles

2018-05-01 thestar.com.my
SINGAPORE: Noble Group Ltd’s dissident shareholder Goldilocks Investment Co listed a raft of hedge funds and banks, including Goldman Sachs Group Inc and Deutsche Bank AG, as defendants in its legal battle against the commodity trader, as the fund presses on with a bid to stop its debt-for-equity swap. (73-0)